Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
NCT00213421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330
Last updated 2013-06-18
Summary
to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.
Conditions
- Bullous Pemphigoid
Interventions
- DRUG
-
Dermoval
group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
Sponsors & Collaborators
-
University Hospital, Rouen
lead OTHER
Principal Investigators
-
Pascal Joly, MD-PHD · UH Rouen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-08-31
- Primary Completion
- 2004-10-31
- Completion
- 2008-11-30
Countries
- France
Study Locations
More Related Trials
-
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
NCT00525616 ·Status: COMPLETED ·Phase: PHASE3
-
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
NCT04035733 ·Status: COMPLETED ·Phase: PHASE2
-
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
NCT04641884 ·Status: UNKNOWN
-
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
NCT01705795 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
NCT02466243 ·Status: TERMINATED ·Phase: PHASE2
-
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02315417 ·Status: TERMINATED ·Phase: PHASE3
-
Severe Bullous Drug Eruption and Filgrastim
NCT04651439 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
NCT00134134 ·Status: COMPLETED ·Phase: PHASE1
-
Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
NCT06479018 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
NCT04117932 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04242498 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03487276 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
NCT00135720 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03628924 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
NCT02874079 ·Status: UNKNOWN ·Phase: NA
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
NCT01987947 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of BAF312 in Dermatomyositis
NCT02029274 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
NCT03248531 ·Status: COMPLETED ·Phase: PHASE2
-
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
NCT00802243 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04242446 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04204616 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT03607487 ·Status: COMPLETED ·Phase: PHASE2